Drug Type Small molecule drug |
Synonyms 3-amino-4-[4- [4- (1-piperidinomethyl)-2-pyridyloxy]-cis-2-butenylamino]-3-cyclobutene-1, 2- dione hydrochloride, Pibutidine, Pibutidine hydrochloride (JAN) + [3] |
Target |
Mechanism H2 receptor antagonists(Histamine H2 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC19H25ClN4O3 |
InChIKeyODBOENMSSFCACZ-PVOKDAACSA-N |
CAS Registry126463-66-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01861 | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Duodenal Ulcer | Phase 3 | JP | - | - |
Duodenal Ulcer | Phase 3 | - | - | |
Duodenal Ulcer | Phase 3 | - | - | |
Peptic Ulcer | Preclinical | JP | 01 Jan 1990 |